Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review

Background: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sezary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL. Objective: Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30* malignancies in humans. Data sources: We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015). Eligibility criteria: Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered. Included studies: A total of 28 articles met these criteria and are summarized in this manuscript. Conclusion: Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30(+) malignancies. (C) 2016 Elsevier Ireland Ltd. All rights reserved.